Europe Antibiotics & Antimycotics Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The European antibiotics and antimycotics market is projected to grow significantly, reaching approximately USD 19.87 billion by 2031, up from USD 13.48 billion in 2023, reflecting a compound annual growth rate (CAGR) of 5.0% during the forecast period.

Executive Summary and Market Analysis

The market is divided into several regions, including the UK, Germany, France, Italy, Spain, and the Rest of Europe. The growth of this market is primarily driven by the rising incidence of bacterial and fungal infections, alongside increasing government initiatives aimed at promoting the responsible use of antibiotics and antimycotics. Additionally, strategic actions such as product launches, regulatory approvals, and collaborations among key industry players are expected to further stimulate market growth in Europe.

Market Segmentation

The analysis of the European antibiotics and antimycotics market is categorized based on drug class, indication, route of administration, and distribution channel:

Drug Class: The market includes various drug classes such as penicillins, cephalosporins, carbapenems, macrolides, aminoglycosides, quinolones, sulfonamides, tetracyclines, azoles, and others. In 2023, penicillins held the largest market share.
Indication: The market is segmented into skin infections, respiratory infections, urinary tract infections (UTIs), septicemia, ear infections, gastrointestinal infections, and others. Respiratory infections accounted for the largest share in 2023.
Route of Administration: This includes oral, topical, and other methods, with oral administration being the most prevalent in 2023.
Distribution Channel: The market is divided into hospital pharmacies, retail pharmacies, and online pharmacies, with hospital pharmacies leading in market share in 2023.

Market Outlook

Companies in the antibiotics and antimycotics sector are actively engaged in developing new products and enhancing existing ones, supported by funding for drug development and clinical trials. Recent developments in the market include:

In September 2024, F2G, a UK-based biopharmaceutical firm, secured USD 100 million to advance the late-stage development of olorofim, a novel oral antifungal treatment for invasive aspergillosis and other fungal infections.
In June 2024, the Global Antibiotic Research & Development Partnership (GARDP) collaborated with Bugworks Research Inc. to develop BWC0977, a broad-spectrum antibiotic targeting multidrug-resistant bacteria.
In June 2023, BioVersys became the first European company to receive funding from the AMR Action Fund for clinical trials aimed at combating bacterial resistance, with plans to launch 2-4 new antimicrobials by 2030.
In October 2022, CARB-X initiated funding rounds focused on critical health needs, including therapeutics for neonatal sepsis and gonorrhea, addressing urgent antimicrobial resistance issues.

These ongoing funding and research initiatives are expected to create significant growth opportunities in the antibiotics and antimycotics market in the coming years.

Country Insights

The market analysis by country reveals that Germany held the largest share in 2023. The growth in Germany is attributed to the high prevalence of bacterial and fungal infections and increased awareness of antimicrobial resistance (AMR). Reports indicate that over 500,000 individuals in Germany are affected by pneumonia annually, with a substantial number requiring hospitalization. Furthermore, the Robert Koch Institute reported that 400,000 to 600,000 patients experience hospital-acquired infections each year, leading to thousands of deaths.

The German government has implemented various initiatives to promote sustainable antibiotic use, including the German Antibiotic Resistance Strategy (DART 2030), which focuses on optimizing prescribing practices. Collaborative efforts among market players, such as the joint venture Aurobac launched by Boehringer Ingelheim, Evotec, and bioMérieux in June 2022, are also expected to enhance market growth.

Company Profiles

Key players in the antibiotics and antimycotics market include Pfizer Inc., Novartis AG, Sanofi SA, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., GSK Plc, Johnson & Johnson, Cipla Ltd, Bayer AG, AbbVie Inc., and Astellas Pharma Inc. These companies are pursuing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative solutions to consumers.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe antibiotics & antimycotics market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in Europe antibiotics & antimycotics market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the antibiotics & antimycotics market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution. Show more